Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract

M. Fragoso, H. Tahi, S. E. Gautier, B. Duchesne, Z. V. Lallet, E. Hernandez, F. Villain, Richard K Parrish, Jean-Marie A Parel

Research output: Contribution to journalArticle

Abstract

Purpose. In vitro and in vivo safety and efficacy evaluation of a CDRi made of poly(D,L-lactide-co-glycolide) 50/50 and a 5-FU antimitotic. Methods. The flexible "C" shaped CDRi device (0.7mm cross-section, 21mm long) contains 2mg of 5-FU and was calculated to release 4.5p,g 5-FU/hr to maintain a = 10[j.g 5-FU/ml concentration in the capsular bag-anterior chamber space, well above therapeutic threshold (= 0.2[4.g/ml) and below toxic level (60|0.rn/ml). In vitro characteristics were assessed in an artificial eye at 36°C with an aqueous flow of 20M-l/min. (10 times normal). The device is inserted in the empty capsular bag using a 19ga instrument. 3 control groups: 6 rabbits without capsule polishing, 6 with capsule polishing, 6 with capsule polishing and a CDRi without 5-FU. A fourth group of 6 receives a 5-FU CDRi. Follow-up stops 1 week after the onset of secondary cataract and histology is performed. Result?. The CDRi released 5-FU for = 50 days m vitro. In vivo, the onset of secondary cataract in controls was =3 weeks. Implant biodégradation takes =100days. The pharmacological, clinical, and histological results of this ongoing study will be presented. Conclusion. The intraocular 5-FU concentrations and long term effect on comeal endothelium have to be further assessed. The 5-FU CDRi needs refinement for insertion though a 3mm corneal incision and is promising.

Original languageEnglish
JournalInvestigative Ophthalmology and Visual Science
Volume38
Issue number4
StatePublished - Dec 1 1997

Fingerprint

Drug Implants
Capsule Opacification
Fluorouracil
Capsules
Artificial Eye
Antimitotic Agents
Drug Liberation
Equipment and Supplies
Poisons
Anterior Chamber
Endothelium
Histology
Pharmacology

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract. / Fragoso, M.; Tahi, H.; Gautier, S. E.; Duchesne, B.; Lallet, Z. V.; Hernandez, E.; Villain, F.; Parrish, Richard K; Parel, Jean-Marie A.

In: Investigative Ophthalmology and Visual Science, Vol. 38, No. 4, 01.12.1997.

Research output: Contribution to journalArticle

Fragoso, M, Tahi, H, Gautier, SE, Duchesne, B, Lallet, ZV, Hernandez, E, Villain, F, Parrish, RK & Parel, J-MA 1997, 'Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract', Investigative Ophthalmology and Visual Science, vol. 38, no. 4.
Fragoso M, Tahi H, Gautier SE, Duchesne B, Lallet ZV, Hernandez E et al. Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract. Investigative Ophthalmology and Visual Science. 1997 Dec 1;38(4).
Fragoso, M. ; Tahi, H. ; Gautier, S. E. ; Duchesne, B. ; Lallet, Z. V. ; Hernandez, E. ; Villain, F. ; Parrish, Richard K ; Parel, Jean-Marie A. / Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract. In: Investigative Ophthalmology and Visual Science. 1997 ; Vol. 38, No. 4.
@article{1ca90bdb0a09496894e63f795ea5188d,
title = "Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract",
abstract = "Purpose. In vitro and in vivo safety and efficacy evaluation of a CDRi made of poly(D,L-lactide-co-glycolide) 50/50 and a 5-FU antimitotic. Methods. The flexible {"}C{"} shaped CDRi device (0.7mm cross-section, 21mm long) contains 2mg of 5-FU and was calculated to release 4.5p,g 5-FU/hr to maintain a = 10[j.g 5-FU/ml concentration in the capsular bag-anterior chamber space, well above therapeutic threshold (= 0.2[4.g/ml) and below toxic level (60|0.rn/ml). In vitro characteristics were assessed in an artificial eye at 36°C with an aqueous flow of 20M-l/min. (10 times normal). The device is inserted in the empty capsular bag using a 19ga instrument. 3 control groups: 6 rabbits without capsule polishing, 6 with capsule polishing, 6 with capsule polishing and a CDRi without 5-FU. A fourth group of 6 receives a 5-FU CDRi. Follow-up stops 1 week after the onset of secondary cataract and histology is performed. Result?. The CDRi released 5-FU for = 50 days m vitro. In vivo, the onset of secondary cataract in controls was =3 weeks. Implant biod{\'e}gradation takes =100days. The pharmacological, clinical, and histological results of this ongoing study will be presented. Conclusion. The intraocular 5-FU concentrations and long term effect on comeal endothelium have to be further assessed. The 5-FU CDRi needs refinement for insertion though a 3mm corneal incision and is promising.",
author = "M. Fragoso and H. Tahi and Gautier, {S. E.} and B. Duchesne and Lallet, {Z. V.} and E. Hernandez and F. Villain and Parrish, {Richard K} and Parel, {Jean-Marie A}",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "38",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "4",

}

TY - JOUR

T1 - Intracapsular controlled drug release implant (CDRi) designed to prevent secondary cataract

AU - Fragoso, M.

AU - Tahi, H.

AU - Gautier, S. E.

AU - Duchesne, B.

AU - Lallet, Z. V.

AU - Hernandez, E.

AU - Villain, F.

AU - Parrish, Richard K

AU - Parel, Jean-Marie A

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Purpose. In vitro and in vivo safety and efficacy evaluation of a CDRi made of poly(D,L-lactide-co-glycolide) 50/50 and a 5-FU antimitotic. Methods. The flexible "C" shaped CDRi device (0.7mm cross-section, 21mm long) contains 2mg of 5-FU and was calculated to release 4.5p,g 5-FU/hr to maintain a = 10[j.g 5-FU/ml concentration in the capsular bag-anterior chamber space, well above therapeutic threshold (= 0.2[4.g/ml) and below toxic level (60|0.rn/ml). In vitro characteristics were assessed in an artificial eye at 36°C with an aqueous flow of 20M-l/min. (10 times normal). The device is inserted in the empty capsular bag using a 19ga instrument. 3 control groups: 6 rabbits without capsule polishing, 6 with capsule polishing, 6 with capsule polishing and a CDRi without 5-FU. A fourth group of 6 receives a 5-FU CDRi. Follow-up stops 1 week after the onset of secondary cataract and histology is performed. Result?. The CDRi released 5-FU for = 50 days m vitro. In vivo, the onset of secondary cataract in controls was =3 weeks. Implant biodégradation takes =100days. The pharmacological, clinical, and histological results of this ongoing study will be presented. Conclusion. The intraocular 5-FU concentrations and long term effect on comeal endothelium have to be further assessed. The 5-FU CDRi needs refinement for insertion though a 3mm corneal incision and is promising.

AB - Purpose. In vitro and in vivo safety and efficacy evaluation of a CDRi made of poly(D,L-lactide-co-glycolide) 50/50 and a 5-FU antimitotic. Methods. The flexible "C" shaped CDRi device (0.7mm cross-section, 21mm long) contains 2mg of 5-FU and was calculated to release 4.5p,g 5-FU/hr to maintain a = 10[j.g 5-FU/ml concentration in the capsular bag-anterior chamber space, well above therapeutic threshold (= 0.2[4.g/ml) and below toxic level (60|0.rn/ml). In vitro characteristics were assessed in an artificial eye at 36°C with an aqueous flow of 20M-l/min. (10 times normal). The device is inserted in the empty capsular bag using a 19ga instrument. 3 control groups: 6 rabbits without capsule polishing, 6 with capsule polishing, 6 with capsule polishing and a CDRi without 5-FU. A fourth group of 6 receives a 5-FU CDRi. Follow-up stops 1 week after the onset of secondary cataract and histology is performed. Result?. The CDRi released 5-FU for = 50 days m vitro. In vivo, the onset of secondary cataract in controls was =3 weeks. Implant biodégradation takes =100days. The pharmacological, clinical, and histological results of this ongoing study will be presented. Conclusion. The intraocular 5-FU concentrations and long term effect on comeal endothelium have to be further assessed. The 5-FU CDRi needs refinement for insertion though a 3mm corneal incision and is promising.

UR - http://www.scopus.com/inward/record.url?scp=33749095492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749095492&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749095492

VL - 38

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 4

ER -